Eledon Pharmaceuticals (ELDN) Income from Continuing Operations (2016 - 2017)
Historic Income from Continuing Operations for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q1 2017 value amounting to -$3.9 million.
- Eledon Pharmaceuticals' Income from Continuing Operations rose 6616.49% to -$3.9 million in Q1 2017 from the same period last year, while for Mar 2017 it was -$30.4 million, marking a year-over-year increase of 2971.82%. This contributed to the annual value of -$36.4 million for FY2024, which is 6883.4% up from last year.
- Eledon Pharmaceuticals' Income from Continuing Operations amounted to -$3.9 million in Q1 2017, which was up 6616.49% from -$3.7 million recorded in Q4 2016.
- Eledon Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$3.7 million for Q4 2016, and its period low was -$13.5 million during Q2 2016.
- In the last 5 years, Eledon Pharmaceuticals' Income from Continuing Operations had a median value of -$7.7 million in 2014 and averaged -$8.3 million.
- In the last 5 years, Eledon Pharmaceuticals' Income from Continuing Operations plummeted by 17357.13% in 2015 and then skyrocketed by 6616.49% in 2017.
- Quarter analysis of 5 years shows Eledon Pharmaceuticals' Income from Continuing Operations stood at -$5.5 million in 2013, then fell by 11.88% to -$6.2 million in 2014, then plummeted by 77.46% to -$11.0 million in 2015, then surged by 66.08% to -$3.7 million in 2016, then dropped by 3.45% to -$3.9 million in 2017.
- Its last three reported values are -$3.9 million in Q1 2017, -$3.7 million for Q4 2016, and -$9.3 million during Q3 2016.